Aug 6 (Reuters) - Medical technology company Heartflow

said on Wednesday it was targeting a valuation of up to $1.46

billion in its upsized initial public offering in the United

States, indicating robust investor demand.

The Mountain View, California-based company is now looking

to raise up to $300 million by offering 16.7 million shares

priced between $17 and $18 apiece.

It had earlier offered 12.5 million shares priced between

$15 and $17 apiece.

Heartflow is among a string of companies racing to go public

before the annual August lull kicks in.

J.P. Morgan, Morgan Stanley ( MS ) and Piper Sandler are the lead

underwriters for the offering.

Heartflow will list on the Nasdaq under the symbol "HTFL".